U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}
Concept
Status:
Possibly Marketed Outside US
First approved in 1994
Source:
BLA103411
Source URL:

Class:
CONCEPT

Concept
Status:
First approved in 1993
Source:
BLA103575
Source URL:

Class:
CONCEPT

Concept
Status:
US Unapproved Medicine
First approved in 2007
Source:
Hematogen by Nnodum Pharmaceuticals
Source URL:

Class:
CONCEPT

Concept
Status:
US Approved Rx (2000)
First approved in 2000
Source:
ANDA089454
Source URL:

Class:
CONCEPT

Concept
Status:
US Approved OTC
Source:
21 CFR 350.10(d) antiperspirant aluminum chlorohydrex propylene glycol
Source URL:
First approved in 1979
Source:
part350
Source URL:

Class:
CONCEPT